CLDX Q1 2020 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+91.4% YoY

Gross Profit

-$9M-328.7% margin

Operating Income

-$13M-471.7% margin

Net Income

-$13M-462.8% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+207.6%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$687,000

Balance Sheet

Total Assets

$113M

Total Liabilities

$29M

Stockholders' Equity

$84M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+91.4%
Gross Profit	-$9M	-$10M	+7.8%
Operating Income	-$13M	-$18M	+28.3%
Net Income	-$13M	-$17M	+26.8%

Revenue Segments

Service

$2M84%

Grant

$442,00016%